Biocompatibles moves into urological devices:
This article was originally published in Clinica
Biocompatibles is to expand into the urology market through the acquisition of German companies Urotech Medizinische Technologie and associated manufacturing company Endo Produktiongesellschaft fur Medical- und Laborprodukte. The acquisition of the two companies, known collectively as Urotech, is valued at around DM15.4 million ($9 million) in new shares. Biocompatibles is expected to apply its phosphorylcholine (PC) coating technology, which is already used in its DivYsio stent, to urological devices. The worldwide urological device market is valued at some $3 billion annually.
You may also be interested in...
Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.
Celltrion has announced plans to add a third biopharmaceutical facility and a new global biotechnology research center at the Korean firm’s existing site in Songdo, Incheon, as the firm also revealed record third-quarter financial results.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.